Quantum BioPharma Outlines Strategy for Lucid-MS and Commercial Growth in BioMedWire Podcast

In a recent episode of the BioMedWire Podcast, Anthony Durkacz, Executive Co-Chairman and Co-Founder of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), discussed the company's strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, and the commercial growth plans surrounding its unbuzzd product. The interview provided insight into how the biopharmaceutical company is balancing clinical-stage development with immediate market opportunities.

Durkacz emphasized that Lucid-MS aims to address mobility damage associated with multiple sclerosis, a key unmet need in the MS treatment landscape. The company has filed an investigational new drug application for a Phase 2 clinical trial, which could represent the first administration of Lucid-MS to human MS patients. This milestone is critical for validating the drug candidate's potential to prevent and reverse myelin degradation, the underlying mechanism of MS, as demonstrated in preclinical models.

In addition to its pharmaceutical pipeline, Quantum BioPharma has commercialized unbuzzd, a product designed to accelerate alcohol metabolism. Durkacz highlighted the strategic importance of this product, noting that it generates revenue while the company advances its clinical programs. Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness Inc. (UWI), the company that markets the OTC version, and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop pharmaceutical versions of the product.

The dual approach allows Quantum BioPharma to generate near-term cash flow from unbuzzd while pursuing long-term value creation through Lucid-MS and other pipeline assets. Durkacz noted that the company is focused on neurodegenerative, metabolic, and alcohol-misuse conditions, providing a diversified portfolio that mitigates risk and maximizes potential returns.

For more details, the full podcast episode is available at https://ibn.fm/IWnPQ. Investors can find the latest news and updates on Quantum BioPharma at https://ibn.fm/QNTM.